Business
REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting
ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- \nData for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy (ALTITUDE®) to be presentedREGENXBIO Inc. (Nasdaq: RGNX) today announced that data from the RGX-314 clinical trials will be presented in three oral presentations at the American Society of Retina Specialists Annual Meeting taking place in San Antonio, TX, from October 8 to 12, 2021. The presentations will include interim results at three months of follow-up for patients in Cohort 1 (dose level: 2.5x1011 genome copies per eye (GC/eye)) of the Phase II ALTITUDE® trial in patients with diabetic retinopathy (DR). This trial is designed to evaluate the in-office, suprachoroidal delivery of RGX-314.\nThe American Society of Retina Specialists Annual Meeting presentations include:\nTitle: Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE StudyPresenter: Dennis Marcus, M.D., F.A.S.R.S., Southeast Retina CenterSession Title: Diabetic Retinopathy 2 SymposiumDate/Time: Saturday, October 9, 2021, from 11:31 to 11:35 a.m. CTType: Oral presentation\nTitle: Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results (Encore Presentation)Presenter: Lejla Vajzovic, M.D., F.A.S.R.S., Surgical & Medical Retina Specialist & Director of Duke Eye Center Continuing Medical EducationSession Title: Wet AMD 1 SymposiumDate/Time: Monday, October 11, 2021, from 8:38 to 8:44 a.m. CT Type: Oral presentation\nTitle: Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study (Encore Presentation)Presenter: Mark Barakat, M.D., F.A.S.R.S., Director of Research, Retinal Consultants of Arizona; Clinical Assistant Professor, University of Arizona College of Medicine, PhoenixSession Title: Wet AMD 1 SymposiumDate/Time: Monday, October 11, 2021, from 8:44 to 8:50 a.m. CTType: Oral presentation\nAbout RGX-314\nRGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow ...